in Asian and Other Diverse Communities
Expert Insight Into:
Long-Term Chronic HBV Therapy with Investigational Nucleoside Associated with Myopathy
Based on the article:
Long-Term Therapy with Clevudine for Chronic Hepatitis B Can Be Associated with Myopathy Characterized by Depletion of Mitochondrial DNA
Medical Writer: Nancy J. Nordenson, MT (ASCP), MFA
Expert Faculty: Steven-Huy B. Han, MD, AGAF
Medical Writer: Nancy J. Nordenson, MT (ASCP), MFA
Expert Faculty: Steven-Huy B. Han, MD, AGAF
Click here to view our current activities in Gastroenterology.
In the first ever report of clevudine-associated myopathy, the paper summarized in this course describes the clinical and pathologic features of the affected patients. Dr. Steven-Huy B. Han reviews the paper’s findings and offers commentary on what these findings mean for clinical practice. This course is part of Advanced Certificate Program IV: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities.
Steven-Huy B. Han, MD, AGAF
- Associate Professor of Medicine & Surgery
- Pfleger Liver Institute
- David Geffen School of Medicine at UCLA
- Los Angeles, California
Robert G. Gish, MD, has received grant/research support from Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffmann-La Roche Inc, Idenix Pharmaceuticals Inc, InterMune Inc, Ortho Biotech Products, LP, Pfizer, Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, and Valeant Pharmaceuticals International; is a consultant for Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, Chiron Corporation, Corixa Corporation, Gilead Sciences, Inc, GlaxoSmithKline, HepaHope, Inc, Hoffmann-La Roche Inc, Human Genome Sciences, Idenix Pharmaceuticals Inc, InterMune Pharmaceuticals, Inc, Metabasis Therapeutics, Inc, Ortho Biotech Products, LP, Pharmasset Pharmaceuticals Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, Valeant Pharmaceuticals International, and ZymoGenetics, Inc; and is on the speakers bureau of Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Hoffmann-La Roche Inc, Schering-Plough Corporation, and Three Rivers Pharmaceuticals International.
Steven-Huy B. Han, MD, AGAF, has received grant/research support from Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffmann-La Roche Inc, and Novartis Pharmaceuticals Corporation; is a consultant for and has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Inc, Pharmasset Pharmaceuticals, Inc, and Novartis Pharmaceuticals Corporation; and is on the speakers bureau of Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffmann-La Roche Inc, and Novartis Pharmaceuticals Corporation.
W. Ray Kim, MD, has received grant/research support from Gilead Sciences, Inc; is a consultant for and is on the advisory boards of Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffman-La Roche, Inc, and Schering-Plough Corporation.
Naoky C.S. Tsai, MD, has received grant/research support from and is on the speakers bureau of Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffmann-La Roche Inc, and Novartis Pharmaceuticals Corporation; and has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Inc, and Novartis Pharmaceuticals Corporation.
Available for CME/CE:
Physicians
Publish Date: Jun 25, 2009 Termination Date: Jun 25, 2010Nurses
Publish Date: Jun 25, 2009 Termination Date: Jun 25, 2010Pharmacists
Publish Date: Jun 25, 2009 Termination Date: Jun 25, 2010Estimated time for completion of this activity:
CNE: 34.80 minutes
CPE: 45.00 minutes
Target Audience
This CME/CE activity is designed for gastroenterologists, hepatologists, infectious disease specialists, nurses, nurse practitioners, pharmacists, physician assistants, and other clinicians, including primary care providers and oncologists, with a special interest in hepatitis B infection.
Activity Goal
The goal of this CME/CE activity is to increase clinicians’ awareness of HBV disease prevalence and diagnostic methodology within the high-risk HBV patient populations, provide current and emerging strategies for the selection of patients for treatment, educate on current treatment options, and expand on treatment management skills for HBV-infected patients.
Learning Objective (s)
- Assess safety issues related to drugs approved or in development for the treatment of chronic hepatitis B to minimize the risk of adverse events in HBV-infected patients undergoing therapy.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
Projects In Knowledge® (PIK) is an approved provider of continuing nursing education by the Delaware Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. PIK provider code: 080903-PROV.
Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.
This activity is approved for 0.58 nursing contact hour(s).
DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, DNA, CBRN, or PIK endorsement of any commercial product or service.
You must complete two article reviews to receive a certificate of 1 or more contact hours. Your statement of credit will be available once you have completed the posttest and evaluation associated with each article review. Projects In Knowledge will record your participation in each article review in your CE tracker.
CE Information: Pharmacists
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This article review is worth up to 0.75 contact hour (0.075 CEU). The ACPE Universal Program Number assigned to this knowledge-type activity is 052-000-09-041-H01-P.
To obtain credit for this activity, you must read the article review carefully,
achieve a passing score on the posttest, and complete and submit the posttest and evaluation.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Steven-Huy B. Han, MD, AGAF has received grant/research support from Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffman La-Roche Inc, and Novartis Pharmaceuticals Corporation; is a consultant for and has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Inc, Novartis Pharmaceuticals Corporation, and Pharmasset Pharmaceuticals, Inc; and is on the speakers bureau of Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffman La-Roche Inc, and Novartis Pharmaceuticals Corporation.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Nancy J. Nordenson, MT (ASCP), MFA has disclosed no significant relationships.
This activity will include a discussion of the drug clevudine, which is not FDA approved for the treatment of chronic hepatitis B infection.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Adrian M. Di Bisceglie, MD, FACP has received grant/research support from Bristol-Myers Squibb, Gilead Sciences, Inc, GlobeImmune, Inc, Hoffman-La Roche, Inc, Idenix Pharmaceuticals, Pharmasset Pharmaceuticals Inc, SciClone Pharmaceuticals, and Vertex Pharmaceuticals Inc; is a consultant for Abbott Laboratories, Bristol-Myers Squibb, Pharmasset Pharmaceuticals Inc, Schering-Plough Corporation, and SciClone Pharmaceuticals; is on the speakers bureau of Bristol-Myers Squibb and Novartis Pharmaceuticals Corporation; and is a member of advisory boards for Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, GlobeImmune, Inc, Hoffman-La Roche, Inc, Idenix Pharmaceuticals, Inc, Metabasis Therapeutics, Novartis Pharmaceuticals Corporation, and Vertex Pharmaceuticals Incorporated.
Robert G. Gish, MD has received grant/research support from Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffmann-La Roche Inc, Idenix Pharmaceuticals Inc, InterMune Inc, Ortho Biotech Products, LP, Pfizer, Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, and Valeant Pharmaceuticals International; is a consultant for Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, Chiron Corporation, Corixa Corporation, Gilead Sciences, Inc, GlaxoSmithKline, HepaHope, Inc, Hoffmann-La Roche Inc, Human Genome Sciences, Idenix Pharmaceuticals Inc, InterMune Pharmaceuticals, Inc, Metabasis Therapeutics, Inc, Ortho Biotech Products, LP, Pharmasset Pharmaceuticals Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, Valeant Pharmaceuticals International, and ZymoGenetics, Inc; and is on the speakers bureau of Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Hoffmann-La Roche Inc, Schering-Plough Corporation, and Three Rivers Pharmaceuticals International.
Steven-Huy B. Han, MD, AGAF has received grant/research support from Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffmann-La Roche Inc, and Novartis Pharmaceuticals Corporation; is a consultant for and has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Inc, Pharmasset Pharmaceuticals, Inc, and Novartis Pharmaceuticals Corporation; and is on the speakers bureau of Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffmann-La Roche Inc, and Novartis Pharmaceuticals Corporation.
W. Ray Kim, MD has received grant/research support from Gilead Sciences, Inc; is a consultant for and is on the advisory boards of Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffman-La Roche, Inc, and Schering-Plough Corporation.
Naoky C.S. Tsai, MD has received grant/research support from and is on the speakers bureau of Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffmann-La Roche Inc, and Novartis Pharmaceuticals Corporation; and has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Inc, and Novartis Pharmaceuticals Corporation.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Available for CME/CE:
Physicians
Publish Date: Jun 25, 2009 Termination Date: Jun 25, 2010Nurses
Publish Date: Jun 25, 2009 Termination Date: Jun 25, 2010Pharmacists
Publish Date: Jun 25, 2009 Termination Date: Jun 25, 2010Estimated time for completion of this activity:
CNE: 34.80 minutes
CPE: 45.00 minutes
Target Audience
This CME/CE activity is designed for gastroenterologists, hepatologists, infectious disease specialists, nurses, nurse practitioners, pharmacists, physician assistants, and other clinicians, including primary care providers and oncologists, with a special interest in hepatitis B infection.
Activity Goal
The goal of this CME/CE activity is to increase clinicians’ awareness of HBV disease prevalence and diagnostic methodology within the high-risk HBV patient populations, provide current and emerging strategies for the selection of patients for treatment, educate on current treatment options, and expand on treatment management skills for HBV-infected patients.
Learning Objective (s)
- Assess safety issues related to drugs approved or in development for the treatment of chronic hepatitis B to minimize the risk of adverse events in HBV-infected patients undergoing therapy.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
Projects In Knowledge® (PIK) is an approved provider of continuing nursing education by the Delaware Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. PIK provider code: 080903-PROV.
Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.
This activity is approved for 0.58 nursing contact hour(s).
DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, DNA, CBRN, or PIK endorsement of any commercial product or service.
You must complete two article reviews to receive a certificate of 1 or more contact hours. Your statement of credit will be available once you have completed the posttest and evaluation associated with each article review. Projects In Knowledge will record your participation in each article review in your CE tracker.
CE Information: Pharmacists
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This article review is worth up to 0.75 contact hour (0.075 CEU). The ACPE Universal Program Number assigned to this knowledge-type activity is 052-000-09-041-H01-P.
To obtain credit for this activity, you must read the article review carefully,
achieve a passing score on the posttest, and complete and submit the posttest and evaluation.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Steven-Huy B. Han, MD, AGAF has received grant/research support from Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffman La-Roche Inc, and Novartis Pharmaceuticals Corporation; is a consultant for and has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Inc, Novartis Pharmaceuticals Corporation, and Pharmasset Pharmaceuticals, Inc; and is on the speakers bureau of Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffman La-Roche Inc, and Novartis Pharmaceuticals Corporation.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Nancy J. Nordenson, MT (ASCP), MFA has disclosed no significant relationships.
This activity will include a discussion of the drug clevudine, which is not FDA approved for the treatment of chronic hepatitis B infection.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Adrian M. Di Bisceglie, MD, FACP has received grant/research support from Bristol-Myers Squibb, Gilead Sciences, Inc, GlobeImmune, Inc, Hoffman-La Roche, Inc, Idenix Pharmaceuticals, Pharmasset Pharmaceuticals Inc, SciClone Pharmaceuticals, and Vertex Pharmaceuticals Inc; is a consultant for Abbott Laboratories, Bristol-Myers Squibb, Pharmasset Pharmaceuticals Inc, Schering-Plough Corporation, and SciClone Pharmaceuticals; is on the speakers bureau of Bristol-Myers Squibb and Novartis Pharmaceuticals Corporation; and is a member of advisory boards for Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, GlobeImmune, Inc, Hoffman-La Roche, Inc, Idenix Pharmaceuticals, Inc, Metabasis Therapeutics, Novartis Pharmaceuticals Corporation, and Vertex Pharmaceuticals Incorporated.
Robert G. Gish, MD has received grant/research support from Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffmann-La Roche Inc, Idenix Pharmaceuticals Inc, InterMune Inc, Ortho Biotech Products, LP, Pfizer, Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, and Valeant Pharmaceuticals International; is a consultant for Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, Chiron Corporation, Corixa Corporation, Gilead Sciences, Inc, GlaxoSmithKline, HepaHope, Inc, Hoffmann-La Roche Inc, Human Genome Sciences, Idenix Pharmaceuticals Inc, InterMune Pharmaceuticals, Inc, Metabasis Therapeutics, Inc, Ortho Biotech Products, LP, Pharmasset Pharmaceuticals Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, Valeant Pharmaceuticals International, and ZymoGenetics, Inc; and is on the speakers bureau of Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Hoffmann-La Roche Inc, Schering-Plough Corporation, and Three Rivers Pharmaceuticals International.
Steven-Huy B. Han, MD, AGAF has received grant/research support from Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffmann-La Roche Inc, and Novartis Pharmaceuticals Corporation; is a consultant for and has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Inc, Pharmasset Pharmaceuticals, Inc, and Novartis Pharmaceuticals Corporation; and is on the speakers bureau of Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffmann-La Roche Inc, and Novartis Pharmaceuticals Corporation.
W. Ray Kim, MD has received grant/research support from Gilead Sciences, Inc; is a consultant for and is on the advisory boards of Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffman-La Roche, Inc, and Schering-Plough Corporation.
Naoky C.S. Tsai, MD has received grant/research support from and is on the speakers bureau of Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffmann-La Roche Inc, and Novartis Pharmaceuticals Corporation; and has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Inc, and Novartis Pharmaceuticals Corporation.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
|



